|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAST3 |
Gene summary for MAST3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAST3 | Gene ID | 23031 |
| Gene name | microtubule associated serine/threonine kinase 3 | |
| Gene Alias | MAST3 | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | O60307 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23031 | MAST3 | HCC1_Meng | Human | Liver | HCC | 3.46e-12 | -3.69e-03 | 0.0246 |
| 23031 | MAST3 | HCC1 | Human | Liver | HCC | 2.93e-04 | 3.09e+00 | 0.5336 |
| 23031 | MAST3 | HCC2 | Human | Liver | HCC | 1.39e-07 | 2.72e+00 | 0.5341 |
| 23031 | MAST3 | S014 | Human | Liver | HCC | 5.35e-12 | 4.94e-01 | 0.2254 |
| 23031 | MAST3 | S015 | Human | Liver | HCC | 9.45e-09 | 4.89e-01 | 0.2375 |
| 23031 | MAST3 | S016 | Human | Liver | HCC | 2.18e-13 | 4.85e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001810511 | Liver | HCC | peptidyl-serine phosphorylation | 169/7958 | 315/18723 | 3.86e-05 | 3.81e-04 | 169 |
| GO:001820911 | Liver | HCC | peptidyl-serine modification | 177/7958 | 338/18723 | 1.45e-04 | 1.17e-03 | 177 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAST3 | SNV | Missense_Mutation | novel | c.548C>G | p.Ala183Gly | p.A183G | O60307 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
| MAST3 | SNV | Missense_Mutation | c.2079N>C | p.Glu693Asp | p.E693D | O60307 | protein_coding | tolerated(0.05) | benign(0.143) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MAST3 | SNV | Missense_Mutation | c.3183N>C | p.Lys1061Asn | p.K1061N | O60307 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MAST3 | SNV | Missense_Mutation | rs759203280 | c.3860N>T | p.Ser1287Leu | p.S1287L | O60307 | protein_coding | tolerated_low_confidence(0.28) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MAST3 | SNV | Missense_Mutation | c.1628C>T | p.Thr543Met | p.T543M | O60307 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MAST3 | SNV | Missense_Mutation | novel | c.3112G>A | p.Glu1038Lys | p.E1038K | O60307 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
| MAST3 | SNV | Missense_Mutation | c.502N>A | p.Glu168Lys | p.E168K | O60307 | protein_coding | deleterious(0) | benign(0.393) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| MAST3 | insertion | Nonsense_Mutation | novel | c.2929_2930insGGATGAGCCCCAGAAGAGGGGAGGAGGAGTAGG | p.Tyr977delinsTrpMetSerProArgArgGlyGluGluGluTerAsp | p.Y977delinsWMSPRRGEEE*D | O60307 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MAST3 | insertion | Frame_Shift_Ins | novel | c.3880_3884dupGAGGG | p.Glu1296ArgfsTer8 | p.E1296Rfs*8 | O60307 | protein_coding | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR | ||
| MAST3 | SNV | Missense_Mutation | novel | c.2152N>T | p.Pro718Ser | p.P718S | O60307 | protein_coding | tolerated_low_confidence(0.8) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23031 | MAST3 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 252827499 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |